Titre
Validation of seven type 2 diabetes mellitus risk scores in a populationbased cohort. The Colaus study
Type
mémoire de master/maîtrise/licence
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Auteur(s)
FABECIC, J.
Auteure/Auteur
Directrices/directeurs
WAEBER, G-
Directeur⸱rice
MEAN, M.
Codirecteur⸱rice
Liens vers les personnes
Liens vers les unités
Faculté
Université de Lausanne, Faculté de biologie et médecine
Statut éditorial
Accepté
Date de publication
2018
Nombre de pages
22
Langue
anglais
Résumé
Objective: Assess the validity of seven type 2 diabetes mellitus (T2DM) risk scores in predicting the 10-year incidence of T2DM in a Swiss population based study.
Methods: prospective study including 5131 participants (55% women, age range 35 to 75 years) living in Lausanne, Switzerland. The baseline survey was conducted between 2003 and 2006 and average follow-up was 10.9 years. Five clinically-based (Balkau, Kahn clinical, Griffin, Swiss diabetes association and Findric) and two clinically and biologically based scores (Kahn CB and Wilson) were tested.
Results: 405 (7.9%) participants developed T2DM. The overall prevalence of participants at high risk ranged from 13.7% for the Griffin score to 43.3% for the Balkau score. Prevalence of participants at high risk among those who developed T2DM ranged from 34.6% for the Griffin score to 82.0% for the Kahn CB score. The Kahn CB score had the highest area under the ROC [value and 95% confidence interval: 0.866 (0.849-0.883)], followed by the Findrisc [0.818 (0.798-0.838)] while the Griffin score had the lowest [0.740 (0.718-0.762)]. Except for the Griffin and the Kahn C scores (for sensitivity) and the Balkau score (for specificity), sensitivities and specificities were above 70%. The numbers needed to screen ranged between 15.5 for the Kahn CB score to 36.7 for the Griffin score.
Conclusion: The Kahn (CB) and the Findrisc performed best of all scores. Findrisc could be used in the epidemiological setting, while the need of blood sampling for the Kahn (CB) score restricts its use to a more clinical setting.
Methods: prospective study including 5131 participants (55% women, age range 35 to 75 years) living in Lausanne, Switzerland. The baseline survey was conducted between 2003 and 2006 and average follow-up was 10.9 years. Five clinically-based (Balkau, Kahn clinical, Griffin, Swiss diabetes association and Findric) and two clinically and biologically based scores (Kahn CB and Wilson) were tested.
Results: 405 (7.9%) participants developed T2DM. The overall prevalence of participants at high risk ranged from 13.7% for the Griffin score to 43.3% for the Balkau score. Prevalence of participants at high risk among those who developed T2DM ranged from 34.6% for the Griffin score to 82.0% for the Kahn CB score. The Kahn CB score had the highest area under the ROC [value and 95% confidence interval: 0.866 (0.849-0.883)], followed by the Findrisc [0.818 (0.798-0.838)] while the Griffin score had the lowest [0.740 (0.718-0.762)]. Except for the Griffin and the Kahn C scores (for sensitivity) and the Balkau score (for specificity), sensitivities and specificities were above 70%. The numbers needed to screen ranged between 15.5 for the Kahn CB score to 36.7 for the Griffin score.
Conclusion: The Kahn (CB) and the Findrisc performed best of all scores. Findrisc could be used in the epidemiological setting, while the need of blood sampling for the Kahn (CB) score restricts its use to a more clinical setting.
PID Serval
serval:BIB_3A3876613A70
Date de création
2019-09-03T07:23:40.076Z
Date de création dans IRIS
2025-05-20T15:29:43Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
Mémoire no 5555 M. Fabecic.pdf
Version du manuscrit
imprimatur
Taille
414.43 KB
Format
Adobe PDF
PID Serval
serval:BIB_3A3876613A70.P001
URN
urn:nbn:ch:serval-BIB_3A3876613A701
Somme de contrôle
(MD5):cc9d0ecc9c7f26785547b526777a4ce4